We’re thrilled to announce that VivoSense will be joining forces with argenx to present at the 8th Annual Digital Biomarkers in Clinical Trials Summit, taking place June 25–26, 2025, at Roche in Basel, Switzerland. This flagship event brings together industry leaders at the intersection of clinical research, digital health, and pharmaceutical innovation to advance the use of digital biomarkers in drug development.
In collaboration with sponsor partner argenx, VivoSense will present a joint session titled:
Unlocking the Value of Patient-Centered Digital Measures: The Importance of an End-to-End Solution
In this joint presentation, VivoSense and argenx will examine a persistent challenge in the field: despite growing enthusiasm for digital measures in clinical trials, many organizations fail to capture their full potential due to fragmented or piecemeal implementation.
We propose a different approach, one that centers the patient and integrates every phase of the digital measure lifecycle. From strategic planning to operational execution and regulatory engagement, an end-to-end solution is key to realizing real-world value from digital endpoints.
What to Expect
Drawing from a real-world collaboration between VivoSense and argenx, our session will present a series of case studies demonstrating how this integrated approach translates into measurable impact:
- – Strategic Alignment: How early partnership between VivoSense and argenx helped identify the most meaningful opportunities for digital measures across the pipeline, aligning with therapeutic and commercial goals.
- – Meaningful Aspects of Health (MAH): How a patient-centered framework enabled the selection of relevant, prioritized concepts of interest, ensuring that digital endpoints reflect what truly matters to patients and support a robust evidence strategy.
- – Operational Oversight: A comparative look at Phase 2 and Phase 3 studies, with and without VivoSense oversight, highlighting improvements in data completeness, monitoring burden, and overall trial efficiency.
- – Analysis and Regulatory Strategy: How coordinated data analysis and insight generation are now supporting broader portfolio decisions at argenx and paving the way for future regulatory submissions.
Why It Matters
This presentation will offer practical insights for sponsors looking to navigate the complexities of digital measure implementation. It also underscores the value of a new kind of CRO model, one designed specifically for patient-centered, digital evidence generation.
At VivoSense, we’re proud to collaborate with forward-thinking partners like argenx who are committed to innovation and patient-centered outcomes. We look forward to sharing our journey at this year’s summit and engaging with other leaders shaping the future of clinical development.
Join us in Basel to learn more!
– Basel, Switzerland
– June 25–26, 2025
If you’re attending the event, we’d love to connect—come join us at the session and learn how we’re helping transform the future of clinical research with digital measures that truly matter.
Register for the Digital Biomarkers in Clinical Trials Summit